Introduction Statins are widely used around the world as one of the most effective lipid-lowering drugs in clinical practice. They work by inhibiting the activity of HMG-CoA reductase, which reduces cholesterol levels and thus lowers the production of low-density lipoprotein cholesterol (LDL-C), decreasing the risk of atherosclerotic cardiovascular disease (ASCVD). According to the World Health Organization, tens of millions of patients are treated with statins each year to prevent cardiovascular events. However, despite the significant efficacy of statins, there are still notable individual differences in their clinical application.
Importance of Genetic Testing It is crucial to perform SLCO1B1 and ApoE genetic testing before statin therapy. The SLCO1B1 gene encodes the OATP1B1 transport protein, which is responsible for the process of statins entering the liver from the blood. Studies have found that carriers of the SLCO1B1*5 and SLCO1B1*15 alleles have a significantly increased risk of statin-associated muscle toxicity, which can lead to discontinuation of the drug due to muscle symptoms or even more serious adverse effects such as rhabdomyolysis. The ApoE gene affects lipid levels and thus modulates the lipid-lowering effects of statins. Individuals carrying the ApoE E2 variant respond better to statin therapy, while those with the ApoE E4 variant often have poor lipid-lowering efficacy. Therefore, genetic testing to assess individual risk and treatment response can achieve personalized and precise statin use.
Wuhan YZY Med SLCO1B1&ApoE Genetic Testing Product The SLCO1B1&ApoE genetic testing product launched by Wuhan YZY Medical Science and Technology Co., Ltd. has gained significant attention in the market due to its high sensitivity and specificity. This product provides a comprehensive genetic risk assessment by detecting two important loci of the SLCO1B1 gene (388A>G and 521T>C3) and two main loci of the ApoE gene (526C>T and ApoE4 388T>C). YZY Med testing product can help identify high-risk individuals to prevent statin-related adverse reactions and provide scientific basis for clinicians to formulate personalized treatment plans. For more details, please visit YZY Med official website: https://www.yzymed.cn/product/human-slco1b1-and-apoe-gene-detection-kit/.
With the development of pharmacogenomics, more and more gene polymorphisms have been shown to be associated with individual differences in statin medication. Achieving personalized statin medication through genetic testing will bring better treatment experiences and outcomes for patients.
